Preexisting evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review.

ABSTRACT:

Background

A minority of phase III trials in gastrointestinal oncology are positive. We assessed the association between their outcome and the level and characteristics of preexisting evidence.

Methods

EMBASE, PubMed, and proceedings from international meetings were searched for phase III gastrointestinal cancer trials (gastroesophageal, hepatocellular, biliary tract, pancreatic, small bowel, colorectal, anal, stromal, and neuroendocrine) between January 2000 and June 2020. Trials investigating anticancer drugs for advanced disease, with superiority design and standard treatments as control were eligible. The highest level of preexisting evidence was retrieved from the main study report.

Results

A total of 193 phase III trials were included, and 69 (35.8%) met their p

SUBMITTER: Bregni G 

PROVIDER: S-EPMC10165488 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature